2025-05-15-Jefferies-因维维德（IVVD）_第一季度销售额较低_但公司在第二季度看到重新加速；上半年实现盈利_11页_997kb

Company Overview: Invivyd is an antibody-based biotech firm focused on viral infectious diseases, notably COVID-19. Its primary product, Pemgarda, is authorized under an EUA for prevention in immunocompromised patients. The company is developing next-generation antibodies to address evolving COVID variants and other diseases, with potential for broader applications.

Q1 Performance: Q1 sales reached $11 million, undershooting consensus estimates of $32 million and Jefferies' $22 million projection. The shortfall resulted from a transition period involving the shift to an internal sales force. Despite this, management anticipates Q2 sales acceleration, citing strong commercial momentum, including record-breaking ever commercial days and weeks, driven by enhanced physician engagement and distribution capabilities.

Financial Highlights: First-quarter operating expenses came in at $27 million, below both consensus ($41 million) and estimates ($30 million), attributed to ongoing cost optimizations. The company projects continued reductions in R&D, COGS, and SG&A expenses. Cash reserves are $48 million, supplemented by a $30 million term loan, supporting commercial execution. Profitability is expected by the end of H1/25, aided by revenue growth and expense control, with GAAP-based monthly profitability reiterated.

Future Outlook and Risks: While Q2 demonstrates improved commercial execution, growth depends on widespread adoption of Pemgarda, potential delays due to variant efficacy concerns, and competition. The company is advancing next-gen mAb '2311, which offers longer half-life, higher potency, and alternative dosing routes. This could expand the market to high-risk populations beyond immunocompromised individuals. Clinically, positive immunobridging data against variants and support from a contemporary trial bolster confidence, but regulatory progression is pending FDA feedback on key pathways. Access and environmental sustainability are noted as challenges, including equity in distribution for lower-income groups and minimizing production impacts.

Investment Thesis: Jefferies maintains a Hold rating with a $0.84 price target and cautions on downside risks. The base-case price assumes moderate sales in later years, reflecting cautious uptake, while upside scenarios to $2.50 depend on strong commercial success. The company may achieve reach profitability by H1/25, with long-term potential in adaptive antibodies, but elevated risks include clinical setbacks, regulatory hurdles, or market reception issues.